AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. Both players are going to face some headwinds over the next couple of years as the income from their cash cow medicines sharply erodes. Beyond that, however, both have big plans to keep growing. But which will grow at a faster pace? Let's look at the arguments for each.

Image source: Getty Images.

The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio. 

Continue reading

Source Fool.com